Pacific Biosciences of California Inc (NASDAQ:PACB) currently has a daily average trading volume of 11.19M but it saw 8589297 shares traded in last market. With a market cap of 366.98M USD, the company’s current market price of $1.34 came falling about -0.74 while comparing to the previous closing price of $1.35. In past 52 weeks, the stock remained buoying in the range of price level as high as $5.01 and as low as $1.16.
Taking a look at 20-day trading activity of Pacific Biosciences of California Inc (PACB) gives us an average price of $1.5352, while its current price level is -73.25% below from 52-week high level whereas it is 15.52% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.6890 while that of 200 days or SMA-200 reads an average of $1.7635. A closer look into the stock’s movement over the week reveals that its volatility is standing at 10.90% during that period while stretching the period over a month that increases to 13.03%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 40.03 which implies that the stock is in neutral territory.
Over the week, PACB’s stock price is moving -17.79% down while it is -8.22% when we observe its performance for the past one month. Year-to-date it is -26.78% down and over the past year, the stock is showing a downside performance of -74.18%.
The company is expected to be releasing its next quarterly report in April, for which analysts forecasted an EPS of -0.19 while estimate for next year EPS is -0.73. In next quarter, company is expected to be making quarterly sales of $38.09M as analysts are expecting the sales for current fiscal year at $161.82M and seeing the company making $204.52M in sales next year. Moreover, analysts are in estimates of $33.66M for current-quarter revenue.
Currently, Pacific Biosciences of California Inc’s total number of outstanding shares is 273.86M with 9.34% of that held by the insiders while 84.99% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -26.15% and return on equity (ROE) at -51.05%. Stock’s beta reads 2.00. Stock has a price to book (P/B) ratio of 0.81 while price to sale or P/S ratio amounts to 2.38. Its return on asset (ROA) is -20.52% on average.
